A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Status:
Unknown status
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the
safety and efficacy of AK102 in patients with heterozygous familial hypercholesterolemia
(HeFH).The primary objective of this study is to evaluate the efficacy of AK102 in patients
with HeFH.
Phase:
Phase 2
Details
Lead Sponsor:
Akeso
Collaborators:
AD Pharmaceuticals Co., Ltd. AD Pharmaceuticals Co., Ltd. (Guangzhou)